For this fall’s issue of Stanford Medicine magazine, which focused on all things digital, I wrote a story featuring the work of Pablo Paredes, PhD, instructor of radiology and of psychiatry and behavioral sciences at Stanford. Paredes aims to enhance people’s mental well-being and reduce stress — his strategy harnesses a suite of technologies, all comforting […]Continue Reading ...
Physician-scientists from Children’s Hospital of Philadelphia (CHOP) presented updated efficacy and safety data on Kymriah(R)* (tisagenlecleucel, formerly CTL019) –the first-ever U.S. Food and Drug Administration (FDA) approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology (ASH) annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell […]Continue Reading ...
CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the […]Continue Reading ...
Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly 610,000 people expected to die from the disease, according to the National Cancer Institute. Fortunately, several recent cancer treatments show considerable promise. Among them is Chimeric Antigen Receptor (CAR) T cell […]Continue Reading ...
Credit: CC0 Public Domain Today, a new blood cancer treatment was approved for use on the NHS in England. And in early September, NHS England announced another, similar treatment will be available to some children and young people with a different type of blood cancer. As with any new drug approval, these announcements are great […]Continue Reading ...
Researchers at the University of Pennsylvania have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy. Image Credit: Juan Gaertner / Shutterstock The study, which was recently published in the journal Nature Medicine, has explained how a single leukemic cell became resistant […]Continue Reading ...
Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is transforming the treatment of solid and hematological cancer by developing the […]Continue Reading ...
August 15, 2018 Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors. The new cells combine two of the most promising types of immunotherapy into one sleek package: chimeric antigen receptor (CAR) T […]Continue Reading ...
In a new study, Indiana University scientists found toxic flame retardants in newly manufactured children’s car seats, sparking concerns about children’s health. Of the 18 children’s car seats tested, 15 contained new or traditional hazardous flame retardant chemicals. “New replacement flame retardants, often marketed as safer alternatives, are lurking in children’s products without rigorous safety […]Continue Reading ...
Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy (CAR-T cell therapy) in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego. Reducing toxicity in CAR-T cell therapy “While CAR-T cell […]Continue Reading ...
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-positive breast cancer patients with brain metastases – is now […]Continue Reading ...
Kidney disease often lacks symptoms until it is at an advanced stage. Credit: Kristoffer Lindskov Hansen, Michael Bachmann Nielsen and Caroline Ewertsen, licensed under CC BY 4.0 Recent advances in kidney research have yielded dramatic headlines touting scientists’ ability to grow kidneys in the lab. But some experts worry that hype about tissue engineering is […]Continue Reading ...
Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma. CAR-T cell therapy has been shown to be remarkably effective in treating cancer patients who have failed standard treatments, but it is expensive and can cause severe side effects. Loyola […]Continue Reading ...
August 21, 2018 CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. Understanding these pathways is important for designing future generations of […]Continue Reading ...
August 14, 2018 University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells. CAR-T therapy has been called a “living drug” and is part of a rapidly emerging immunotherapy approach called adoptive cell transfer […]Continue Reading ...
- Effects of linoleic acid on the body are largely dependent on genes, shows study
- Pre-injury exercise reduces damage to both muscles and nerves, study finds
- Minimizing Antibody Size to Maximize Research Potential
- Research finds large genome in tiny forest defoliator
- Technology helps reduce the yearning for unhealthy food
- New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
- What you should know about teeth whitening
- Why Older Adults Should Eat More Protein (And Not Overdo Protein Shakes)
- Colorectal cancer mortality rates predicted to increase globally
- Scientists discover mutational signatures of tumor hypoxia
- New evidence shows how fever alters immune cells
- Researchers find new class of blood pressure-regulating peptides in vampire bat venom
- Promega to exhibit new Maxwell RSC48 platform at 2019 Festival of Genomics
- Study pinpoints immune cells that could be key to tackling hypertension
- Couples Intervention May Aid Partners of Diabetes Patients
- Your weight history may predict your heart failure risk
- Explore a cornucopia of accomplishments in prematurity research
- New study identifies four characteristics that predict severity of postpartum depression
- New, scalpel-free treatment for reducing Parkinson’s tremor gets FDA approval
- Neurobiologists uncover key component of how the human brain marks time